236 related articles for article (PubMed ID: 30504931)
1. Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels.
Lee K; Seifert BA; Shimelis H; Ghosh R; Crowley SB; Carter NJ; Doonanco K; Foreman AK; Ritter DI; Jimenez S; Trapp M; Offit K; Plon SE; Couch FJ
Genet Med; 2019 Jul; 21(7):1497-1506. PubMed ID: 30504931
[TBL] [Abstract][Full Text] [Related]
2. Determining the clinical validity of hereditary colorectal cancer and polyposis susceptibility genes using the Clinical Genome Resource Clinical Validity Framework.
Seifert BA; McGlaughon JL; Jackson SA; Ritter DI; Roberts ME; Schmidt RJ; Thompson BA; Jimenez S; Trapp M; Lee K; Plon SE; Offit K; Stadler ZK; Zhang L; Greenblatt MS; Ferber MJ
Genet Med; 2019 Jul; 21(7):1507-1516. PubMed ID: 30523343
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the strength of evidence for genes implicated in peroxisomal disorders using the ClinGen clinical validity framework and providing updates to the peroxisomal disease nomenclature.
Mohan S; Mayers M; Weaver M; Baudet H; De Biase I; Goldstein J; Mao R; McGlaughon J; Moser A; Pujol A; Suchy S; Yuzyuk T; Braverman NE
Mol Genet Metab; 2023 Jul; 139(3):107604. PubMed ID: 37236006
[TBL] [Abstract][Full Text] [Related]
4. Assessing the strength of evidence for genes implicated in fatty acid oxidation disorders using the ClinGen clinical validity framework.
McGlaughon JL; Pasquali M; Wallace K; Ross J; Senol-Cosar O; Shen W; Weaver MA; Feigenbaum A; Lyon E; Enns GM; Mao R; Baudet HG
Mol Genet Metab; 2019; 128(1-2):122-128. PubMed ID: 31399326
[TBL] [Abstract][Full Text] [Related]
5. Impact of Panel Gene Testing for Hereditary Breast and Ovarian Cancer on Patients.
Lumish HS; Steinfeld H; Koval C; Russo D; Levinson E; Wynn J; Duong J; Chung WK
J Genet Couns; 2017 Oct; 26(5):1116-1129. PubMed ID: 28357778
[TBL] [Abstract][Full Text] [Related]
6. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
[TBL] [Abstract][Full Text] [Related]
7. Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing.
Lu HM; Li S; Black MH; Lee S; Hoiness R; Wu S; Mu W; Huether R; Chen J; Sridhar S; Tian Y; McFarland R; Dolinsky J; Tippin Davis B; Mexal S; Dunlop C; Elliott A
JAMA Oncol; 2019 Jan; 5(1):51-57. PubMed ID: 30128536
[TBL] [Abstract][Full Text] [Related]
8. "Decoding hereditary breast cancer" benefits and questions from multigene panel testing.
Colas C; Golmard L; de Pauw A; Caputo SM; Stoppa-Lyonnet D
Breast; 2019 Jun; 45():29-35. PubMed ID: 30822622
[TBL] [Abstract][Full Text] [Related]
9. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
10. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
[TBL] [Abstract][Full Text] [Related]
11. ClinGen expert clinical validity curation of 164 hearing loss gene-disease pairs.
DiStefano MT; Hemphill SE; Oza AM; Siegert RK; Grant AR; Hughes MY; Cushman BJ; Azaiez H; Booth KT; Chapin A; Duzkale H; Matsunaga T; Shen J; Zhang W; Kenna M; Schimmenti LA; Tekin M; Rehm HL; Tayoun ANA; Amr SS;
Genet Med; 2019 Oct; 21(10):2239-2247. PubMed ID: 30894701
[TBL] [Abstract][Full Text] [Related]
12. The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program.
Bunnell AE; Garby CA; Pearson EJ; Walker SA; Panos LE; Blum JL
J Genet Couns; 2017 Feb; 26(1):105-112. PubMed ID: 27276934
[TBL] [Abstract][Full Text] [Related]
13. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
[TBL] [Abstract][Full Text] [Related]
14. A new paradigm of genetic testing for hereditary breast/ovarian cancers.
Kwong A; Chen JW; Shin VY
Hong Kong Med J; 2016 Apr; 22(2):171-7. PubMed ID: 26980575
[TBL] [Abstract][Full Text] [Related]
15. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.
Li J; Meeks H; Feng BJ; Healey S; Thorne H; Makunin I; Ellis J; ; Campbell I; Southey M; Mitchell G; Clouston D; Kirk J; Goldgar D; Chenevix-Trench G
J Med Genet; 2016 Jan; 53(1):34-42. PubMed ID: 26534844
[TBL] [Abstract][Full Text] [Related]
16. Occurrence of variants of unknown clinical significance in genetic testing for hereditary breast and ovarian cancer syndrome and Lynch syndrome: a literature review and analytical observational retrospective cohort study.
Adam F; Fluri M; Scherz A; Rabaglio M
BMC Med Genomics; 2023 Jan; 16(1):7. PubMed ID: 36647026
[TBL] [Abstract][Full Text] [Related]
17. A research-based gene panel to investigate breast, ovarian and prostate cancer genetic risk.
Bishop MR; Huskey ALW; Hetzel J; Merner ND
PLoS One; 2019; 14(8):e0220929. PubMed ID: 31415627
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the clinical validity of genes related to hemostasis and thrombosis using the Clinical Genome Resource gene curation framework.
Ross JE; Mohan S; Zhang J; Sullivan MJ; Bury L; Lee K; Futchi I; Frantz A; McDougal D; Perez Botero J; Cattaneo M; Cooper N; Downes K; Gresele P; Keenan C; Lee AI; Megy K; Morange PE; Morgan NV; Schulze H; Zimowski K; Freson K; Lambert MP
J Thromb Haemost; 2024 Mar; 22(3):645-665. PubMed ID: 38016518
[TBL] [Abstract][Full Text] [Related]
19. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
Moretta J; Berthet P; Bonadona V; Caron O; Cohen-Haguenauer O; Colas C; Corsini C; Cusin V; De Pauw A; Delnatte C; Dussart S; Jamain C; Longy M; Luporsi E; Maugard C; Nguyen TD; Pujol P; Vaur D; Andrieu N; Lasset C; Noguès C;
Bull Cancer; 2018 Oct; 105(10):907-917. PubMed ID: 30268633
[TBL] [Abstract][Full Text] [Related]
20. Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication.
Pelttari LM; Shimelis H; Toiminen H; Kvist A; Törngren T; Borg Å; Blomqvist C; Bützow R; Couch F; Aittomäki K; Nevanlinna H
Clin Genet; 2018 Mar; 93(3):595-602. PubMed ID: 28802053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
